Prospective surveillance of hospital associated infections epidemiology in a haematology-oncology department

Nabiha Bouafia,Olfa Ezzi,Mansour Njah,Wadiaa Bannour,Arwa Ben Salah,Asma Ben Chiekh,Bechir Achour,Radhia Helali,Abderrahim Khelif,Ben Slimene Dalel,Asma Ammar,Mohamed Mahjoub

doi:10.3396/ijic.v15i1.002.19

Abstract

In haematology-oncology, intensified procedures have been associated with higher risk of healthcare associated infections (HAIs).This study aimed to estimate the incidence and to identify risk factors of HAIs in a haematology-oncology unit in a Tunisian university hospital. We conducted a prospective study, during 06 months from Mars through September 2016 in the department of hematology- oncology in a tertiary teaching hospital in Tunisia. Patients, admitted for ≥48 h, were followed until hospital discharge. The (CDC) criteria for site-specific infections were used to define HAIs. Bivariate and multivariate analyses were performed to identify risk factors of HAIs. P

Highlights

Over the past few decades, major progress has been made in the curative treatment of haematological malignancies which has resulted in reduced overall mortality.[1]
Since 2016, a large prospective surveillance program was launched in several departments by the infection control department, and to our knowledge this is the first prospective study conducted in the haematologyoncology unit aiming to evaluate healthcare-associated infections (HAIs)
Concerning the patients’ diagnosis, the highest incidence rate of HAIs was observed in patients with acute myeloid leukaemia (53.57/100 patients), followed by non-Hodgkin’s lymphoma (35.71/100 patients), acute lymphoblastic leukaemia (28.75/100 patients), and Hodgkin’s lymphoma (10.0/100 patients)

Summary

Introduction

Over the past few decades, major progress has been made in the curative treatment of haematological malignancies which has resulted in reduced overall mortality.[1] This improvement has allowed increasingly aggressive management in diagnostic and therapeutic procedures.[2] chemotherapy, bone marrow or peripheral blood stem cell transplantation This could lead to severe and prolonged immunosuppression, increasing the risk of healthcare-associated infections (HAIs) and possibly worsening the prognosis.[3] HAIs are important adverse events in the disease history of patients with haematological malignancies, sometimes culminating in death; they are responsible for longer hospital stay and increased healthcare costs.[4]. In 2009, the incidence of serious adverse events including HAIs in medical departments was 13.7%.5 Since 2016, a large prospective surveillance program was launched in several departments by the infection control department, and to our knowledge this is the first prospective study conducted in the haematologyoncology unit aiming to evaluate HAIs

Objectives

Methods

Results

Discussion

Conclusion